GHB

Time to collection is the dominant variable in any GHB investigation, far more important than dose or donor characteristics. GHB follows first-order elimination kinetics with a serum half-life of roughly 30–60 minutes, which means that any single recreational or DFSA dose is largely cleared from blood within 4–6 hours and from urine within 8–12 hours. Forensic guidance for suspected DFSA accordingly emphasizes collecting both blood and urine as soon as the patient or victim is in care, and documenting the precise time of every collection alongside the suspected exposure time. The kinetic ceiling on detection is biological, not analytical — no matter how sensitive the laboratory method, a sample collected outside the window cannot recover a result that the body has already cleared.

Endogenous GHB concentrations in living donors typically sit well below 4 mcg/mL in urine and well below 1 mg/L in blood, but the exact baseline varies between individuals and rises post-mortem due to bacterial production. Quantitative interpretation must account for this. The 10 mcg/mL urine cutoff commonly used by forensic laboratories to distinguish exogenous from endogenous exposure is a conservative threshold; values close to but above the cutoff warrant cautious interpretation and consideration of collection delay, sample storage, and post-mortem interval where applicable. Pediatric and neonatal forensic cases require particular care because reference ranges for younger donors are less well established.

Metabolism is rapid and proceeds via the GHB dehydrogenase pathway with onward oxidation through succinic semialdehyde to succinate, ultimately entering the tricarboxylic acid cycle as CO2 and water. Hepatic enzymes including alcohol dehydrogenase contribute to clearance of the precursors GBL and 1,4-butanediol, with 1,4-butanediol metabolized to GHB primarily by alcohol dehydrogenase — which is why concurrent ethanol consumption can transiently slow 1,4-butanediol clearance through competitive inhibition. The CYP enzyme system plays a minor role compared with the soluble dehydrogenases, so the standard CYP-mediated drug-drug interactions that dominate other substances are less prominent for GHB. Hepatic impairment from cirrhosis or active hepatitis modestly extends the window but rarely changes the operational picture: the dominant issue remains time to collection.

Sample handling materially affects GHB results. GHB is unstable in stored samples — bacterial activity can generate GHB post-collection, particularly in samples held at room temperature or contaminated with skin flora during collection. Forensic toxicology protocols therefore specify rapid refrigeration or freezing of all GHB specimens, preservation with sodium fluoride for blood, and explicit documentation of the cold chain from collection through analysis. Failure to follow these protocols can produce falsely elevated results that cannot reliably be attributed to exogenous exposure. Renal function affects the rate of urinary clearance but does not extend the practical window significantly given the short underlying half-life; even donors with reduced creatinine clearance generally fall within the standard 8–12 hour urinary window.

Concomitant ethanol or other depressant use does not meaningfully change GHB pharmacokinetics but does increase clinical sedation and the likelihood that a donor will present to care after the GHB-detection window has closed. This is part of why GHB toxicology results in real-world DFSA investigations are often negative even when GHB exposure is suspected — the practical window between exposure and emergency-department presentation routinely exceeds 8–12 hours. Negative GHB toxicology in such cases does not rule out exposure; it reflects the kinetics. Sexual-assault response programs increasingly document this limitation explicitly in their evidence-collection protocols so that downstream investigators understand that a negative result is not exonerating.

GHB is NOT included in the SAMHSA Mandatory Guidelines for federal workplace drug testing, and the Department of Transportation panel — which follows the SAMHSA Mandatory Guidelines — does not include GHB either. The SAMHSA-5 panel covers marijuana, cocaine, amphetamines, opiates, and PCP. There is no SAMHSA-recommended cutoff or method for GHB and no SAMHSA-certified workplace pathway. Programs that need GHB testing arrange it as a specialty laboratory analysis outside the federal panel, typically through a reference toxicology laboratory rather than through any CLIA-waived point-of-care device.

The industry-standard urinary cutoff for distinguishing exogenous GHB exposure from endogenous baseline is approximately 10 mcg/mL (10,000 ng/mL), with confirmation by GC-MS or LC-MS/MS. Forensic laboratories typically use this threshold in DFSA panels. Some clinical laboratories report quantitatively against the endogenous reference range rather than a binary cutoff, providing the absolute concentration plus context for interpretation. Blood and serum cutoffs are correspondingly lower and laboratory-specific. Because GHB analysis is laboratory-based rather than immunoassay-based, the conventional immunoassay-to-confirmation gap that exists for other analytes does not apply in the same way — but the analogous gap is between an unverified quantitative result and one that has been reviewed against the laboratory\'s reference range, the chain-of-custody record, and any prescription documentation for sodium oxybate.

Patients receiving Xyrem or Xywav (sodium oxybate or mixed-salt oxybate) for narcolepsy will produce positive GHB results during the active dosing window — typically a few hours after each scheduled dose. Any positive GHB result in a donor with a documented Xyrem or Xywav prescription should be reviewed by a Medical Review Officer with reference to the REMS-documented dosing schedule. Because oxybate is dosed at bedtime and again in the middle of the night, urine collections in the morning may be positive even for compliant patients. MRO review is the operational checkpoint that distinguishes a defensible verified result from a raw analytical positive, and it is where REMS documentation, prescription history, and laboratory quantitation come together to produce an actionable interpretation. In DFSA contexts, the equivalent function is performed by the forensic toxicologist and prosecuting attorney, with the laboratory report serving as the primary evidentiary artifact.

There is no routine commercial point-of-care immunoassay device for GHB. Unlike most analytes covered on this site, GHB testing is performed exclusively by laboratory mass spectrometry — typically gas chromatography-mass spectrometry (GC-MS) after derivatization, or liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a validated method. Programs that need GHB testing arrange specimen collection and laboratory shipping rather than relying on a lateral-flow device. This absence of a point-of-care option is a structural feature of the analyte, not a market gap: the combination of short detection window, endogenous baseline, and small molecular size makes immunoassay development for GHB technically and commercially difficult.

Sample preparation for GHB analysis is more involved than for other analytes. Urine specimens are typically diluted, GHB and the internal standard (deuterated GHB) are extracted, and the analytes are derivatized — most commonly by silylation with BSTFA or by conversion to the trifluoroacetyl ester — to a form suitable for chromatographic separation. Blood specimens require additional protein precipitation, and some laboratories use direct-injection LC-MS/MS methods that avoid derivatization altogether. The methods are validated for linearity, specificity, and stability in the relevant biological matrix, and quantitation is reported with explicit reference to the laboratory\'s endogenous-baseline reference range. ABFT- and CAP-accredited laboratories publish their validation data and stand behind their methods in court when forensic results are challenged.

Because there is no immunoassay step, the cross-reactivity considerations that dominate other analytes do not apply to GHB. The relevant analytical pitfalls are instead in sample handling, post-collection GHB generation by bacterial activity, and matrix effects in the mass spectrometer. Laboratories validated for forensic GHB analysis publish their stability and recovery data and follow accreditation standards from the American Board of Forensic Toxicology and the College of American Pathologists. Common matrix-related issues include ion suppression from concentrated urine, carryover in autosamplers between high- and low-concentration specimens, and isobaric interference from related short-chain hydroxyacids that requires careful selection of MRM transitions.

Confirmation by a second, orthogonal mass-spectrometry method is standard in forensic GHB workups, particularly in DFSA cases where a quantitative result will be used as evidence. Forensic reports include the quantitative result, the laboratory\'s stated endogenous reference range, the time of collection relative to the suspected exposure event, and a qualitative interpretation. The treating clinician or sexual-assault nurse examiner should document the chain of custody from collection through laboratory receipt — every transfer, every storage interval, every temperature deviation. Observed collection is the norm in DFSA evidence kits, with the SANE or trained collector physically present throughout. In other GHB-testing contexts (clinical monitoring of oxybate adherence, post-mortem casework) the collection model varies but chain-of-custody documentation remains the backbone of any defensible result.

Specimen integrity testing in the conventional immunoassay sense (creatinine, specific gravity, pH, oxidant adulterants) is less central to GHB analysis because the test is quantitative and laboratory-based rather than competing for limited cutoff space on a lateral-flow strip. However, gross dilution, addition of preservatives that interfere with derivatization, and visible degradation should be documented and may prompt the laboratory to qualify the report. Random, reasonable-suspicion, and post-incident testing protocols all apply in their respective non-forensic GHB-testing contexts, though the short detection window means random programs rarely capture GHB exposure in practice — reasonable-suspicion and post-incident collection within hours of the event remain the only reliably productive protocols for this analyte.